Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib by Rini, Brian I. et al.
jnci.oxfordjournals.org    JNCI | Articles 763
DOI: 10.1093/jnci/djr128  © The Author 2011. Published by Oxford University Press. All rights reserved.
Advance Access publication on April 28, 2011.  This is an Open Access article distributed under the terms of the Creative Commons Attribution
  Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted
  non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Hypertension (HTN) is commonly associated with angiogenesis 
inhibitors  that  target  the  vascular  endothelial  growth  factor 
(VEGF) pathway and appears to be a generalized effect of this class 
of agents, including sunitinib, bevacizumab, sorafenib, and axitinib, 
which are newly developed targeted therapies for metastatic renal 
cell carcinoma (1–6). Physiologically, HTN develops when VEGF 
stimulates production of nitric oxide and prostacyclins in vascular 
endothelial cells (7,8), vasodilatory mechanisms become inhibited, 
and peripheral vascular resistance increases, leading to increased 
blood pressure (BP). In addition, there is evidence to suggest that 
HTN may result from structural or functional vascular rarefaction 
caused by inhibition of angiogenic growth factors (9). HTN may 
also result from decreased glomerular filtration rate and increased 
sodium and water retention by the kidney, similar to pre-eclampsia-
associated  HTN,  which  has  been  linked  to  placental-derived   
soluble antiangiogenic factors including VEGF (10).
Sunitinib malate (SUTENT; Pfizer Inc, New York, NY) is an 
orally administered receptor tyrosine kinase inhibitor that targets 
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  Background  Hypertension (HTN) is an on-target effect of the vascular endothelial growth factor pathway inhibitor, sunitinib. 
We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse 
events  in patients with metastatic renal cell carcinoma.
  Methods  This retrospective analysis included pooled efficacy (n = 544) and safety (n = 4917) data from four studies of 
patients  with  metastatic  renal  cell  carcinoma  who  were  treated  with  sunitinib  50  mg/d  administered  on  a 
4-week-on 2-week-off schedule (schedule 4/2). Blood pressure (BP) was measured in the clinic on days 1 and 28 
of each 6-week cycle. Progression-free survival (PFS) and overall survival (OS) were estimated using Kaplan–
Meier methods; hazard ratios (HRs) for survival were also estimated by a Cox proportional hazards models 
using HTN as a time-dependent covariate. Efficacy outcomes were compared between patients with and with-
out HTN (maximum systolic BP [SBP] ≥140 mm Hg or diastolic BP [DBP] ≥90 mm Hg). Adverse events were also 
compared between patients with and without HTN (mean SBP ≥140 mm Hg or mean DBP ≥90 mm Hg). All 
P values were two-sided.
  Results  Patients with metastatic renal cell carcinoma and sunitinib-induced HTN defined by maximum SBP had better 
outcomes than those without treatment-induced HTN (objective response rate: 54.8% vs 8.7%; median PFS: 12.5 
months, 95% confidence interval [CI] = 10.9 to 13.7 vs 2.5 months, 95% CI = 2.3 to 3.8 months; and OS: 30.9 
months, 95% CI = 27.9 to 33.7 vs 7.2 months, 95% CI = 5.6 to 10.7 months; P < .001 for all). Similar results were 
obtained when comparing patients with vs without sunitinib-induced HTN defined by maximum DBP. In a Cox 
proportional hazards model using HTN as a time-dependent covariate, PFS (HR of disease progression or death 
= .603, 95% CI = .451 to .805; P < .001) and OS (HR of death = .332, 95% CI = .252 to .436; P < .001) were improved 
in patients with treatment-induced HTN defined by maximum SBP; OS (HR of death = .585, 95% CI = .463 to .740; 
P < .001) was improved in patients with treatment-induced HTN defined by maximum DBP, but PFS was not. 
Few  any-cause  cardiovascular,  cerebrovascular,  ocular,  and  renal  adverse  events  were  observed.  Rates  of 
adverse events were similar between patients with and without HTN defined by mean SBP; however, hyperten-
sive patients had somewhat more renal adverse events (5% vs 3%; P = .013).
  Conclusions  In patients with metastatic renal cell carcinoma, sunitinib-associated HTN is associated with improved clinical 
outcomes without clinically significant increases in HTN-associated adverse events, supporting its viability as an 
efficacy biomarker.
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VEGF  receptors  and  other  receptor  tyrosine  kinases  (PDGFR, 
KIT, FLT-3, CSF-1R, and RET). Sunitinib has been approved 
worldwide for the treatment of advanced renal cell carcinoma. In a 
randomized phase III trial that tested first-line therapy for meta-
static renal cell carcinoma (11), sunitinib was superior to inter-
feron-a in progression-free survival (PFS; 11 vs 5 months; P < .001) 
and objective response rate (ORR; 47% vs 12%; P < .001); in addi-
tion, median overall survival (OS) with sunitinib was 26.4 vs 21.9 
months with interferon-a. Based on these data, sunitinib is cur-
rently a standard initial treatment for patients with advanced renal 
cell carcinoma. Sunitinib was also associated with a 34% incidence 
of any-grade HTN (including a 13% incidence of grade 3 HTN), 
which was reported as an adverse event in this trial (12).
Treatment-induced  HTN  has  been  proposed  as  a  potential 
biomarker  of  the  clinical  effect  of  antiangiogenic  agents.  For   
example, in a retrospective analysis across multiple tumor types, we 
demonstrated an association between the occurrence of diastolic 
BP (DBP) of at least 90 mm Hg and clinical outcome in patients 
(most  notably  those  with  metastatic  renal  cell  carcinoma)  who 
received the potent and selective VEGF receptor inhibitor axitinib 
(13).  In  addition,  the  onset  of  HTN  has  been  associated  with 
improved  clinical  outcome  in  patients  receiving  other  targeted 
agents, such as those who received the anti–VEGF monoclonal 
antibody bevacizumab for the treatment of multiple tumor types 
that included advanced renal cell carcinoma, non–small cell lung 
cancer, and pancreatic and colorectal cancers (14–17).
Based on these observations, a retrospective analysis was per-
formed to evaluate whether the development of HTN in sunitinib-
treated patients with metastatic renal cell carcinoma was associated 
with its antitumor efficacy and development of HTN-associated 
complications in target organs. From this study, we sought to deter-
mine whether sunitinib-associated HTN could be a biomarker of 
efficacy without unacceptable toxicity. To our knowledge, the cur-
rent report represents the largest retrospective analysis of a VEGF 
receptor inhibitor in a uniform disease state. Efficacy and safety data 
were pooled from three clinical trials of single-agent sunitinib, and 
the  safety  analysis  additionally  included  data  from  an  expanded   
access protocol that enrolled more than 4000 patients (18).
Subjects and Methods
Patients
Data from sunitinib-treated patients in four clinical trials were in-
cluded in this analysis: two second-line phase II trials (N = 63 and 
N = 106), one first-line phase III trial (N = 375), and an expanded 
access trial (N = 4371) (18–21). Common eligibility criteria for all 
patients in these analyses included age 18 years or older with histo-
logically confirmed metastatic renal cell carcinoma, adequate organ 
function,  absence  of  any  clinically  significant  cardiac  events  (in-
cluding myocardial infarction, congestive heart failure, or coronary 
artery bypass graft) within 6 or 12 months of study entry depending 
on the protocol, and the absence of cardiac dysrhythmia or severe 
or unstable angina, either ongoing or within 12 months of study 
entry. Common eligibility criteria for patients that were in the effi-
cacy  analysis  also  included  the  presence  of  measurable  disease, 
absence  of  known  brain  metastases,  an  Eastern  Cooperative 
Oncology Group performance status (ECOG PS) of 0 or 1, and 
normal QTc interval. Uncontrolled HTN was explicitly listed as an 
exclusion criterion in the two phase II trials included in this analysis.
Design
To investigate the relationship between HTN and antitumor effi-
cacy, this retrospective analysis included pooled data from 544 suni-
tinib-treated metastatic renal cell carcinoma patients in the three 
prospective multinational clinical trials (19–21). Ten patients were 
excluded due to lack of post-baseline BP. Patients were administered 
sunitinib as either second- or first-line treatment of metastatic renal 
cell  carcinoma  as  noted  above.  Sunitinib  was  administered  at  a   
starting dose of 50 mg orally once daily for 4 consecutive weeks 
followed by 2 weeks off treatment (schedule 4/2) in repeated 6-week 
cycles until progression of disease, lack of clinical benefit, or unac-
ceptable toxicity. Antihypertensive medications and/or sunitinib dose 
schedule modifications were used to manage HTN as per each clin-
ical trial protocol and at the discretion of the investigator. Efficacy 
CONTEXT AND  CAVEATS
Prior knowledge
Hypertension  (HTN)  is  a  well-known  side  effect  in  some  cancer 
patients  who  are  treated  with  the  vascular  endothelial  growth 
factor  pathway  inhibitor,  sunitinib,  but  it  was  not  clear  whether 
sunitinib-induced HTN is a biomarker of cancer treatment efficacy.
Study design
A retrospective efficacy analysis measured the association of suni-
tinib-induced HTN with progression-free survival, overall survival, 
and hazard ratios for survival using data from two phase II trials (N 
= 63 and N = 106) and one phase III trial (N = 375) for metastatic 
renal cell carcinoma. In parallel analyses, HTN was defined by either 
maximum systolic blood pressure (SBP, ≥140 mm Hg  ) or max-
imum diastolic blood pressure (DBP, ≥90 mm Hg). A retrospective 
safety analysis examined the association of sunitinib-induced HTN 
with adverse events using data from the same three trials and from 
an  additional  expanded  access  trial  (N  =  4371).  In  the  safety 
analysis, HTN was defined by a mean SBP of at least 140 mm Hg.
Contribution
Metastatic  renal  carcinoma  patients  with  sunitinib-induced  HTN 
defined by maximum SBP (≥140 mm Hg) had longer progression-free 
survival and overall survival than patients without treatment-induced 
HTN. Results were similar for patients with sunitinib-induced HTN 
defined by DBP. Overall survival appeared to be improved in patients 
with both SBP- and DBP-defined HTN. HTN-associated adverse events 
were slightly higher in patients with a mean SBP at or above (vs 
below) 140 mm Hg (overall, 11% vs 9%, for renal events, 5% vs 3%).
Implications
The association of sunitinib-induced HTN with improved survival 
makes  it  a  potential  biomarker  for  treatment  efficacy  among 
patients with metastatic renal cell carcinoma.
Limitations
The results were drawn retrospectively from four clinical trials with 
variable populations and parameters. Some patients were given 
antihypertensive drugs, and it is not entirely clear how this affects 
the data. For HTN to be considered a true biomarker in this setting, 
a validation set and further prospective trials would be needed.
From the Editors
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was measured as ORR [the proportion of patients who had either a 
complete or partial response as assessed by investigators according to 
Response Evaluation Criteria in Solid Tumors (22)], PFS, and OS.
The safety portion of the analysis was augmented to include 
patients from an expanded access trial of metastatic renal cell car-
cinoma (18) that provided an additional 4373 patients, bringing the 
total sample size to 4917 patients. Because they lacked post-baseline 
BP  measurements,  498  patients  were  excluded.  The  HTN-
associated  complications  evaluated  in  this  analysis  included 
prespecified  cardiovascular,  cerebrovascular,  ocular,  and  renal 
adverse events as described by Chobanian et al. (23). Adverse events 
were graded according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), version 3.0.
HTN  was  defined  by  either  maximum  or  mean  systolic  BP 
(SBP) of at least 140 mm Hg or DBP of at least 90 mm Hg, as 
measured in the clinic on days 1 and 28 of each 6-week treatment 
cycle at any time during the study after the first dose of sunitinib. 
These thresholds were prospectively chosen before data analysis 
based on published guidelines (23). Maximum (and not mean) SBP 
and DBP were used for efficacy analyses because subsequent dose 
reduction of sunitinib and/or antihypertensive medication could 
have affected mean BP values. Mean (not maximum) SBP and DBP 
were used for safety analyses and were calculated based on an average 
of eight post-baseline measurements over a range of 1–33 cycles.
Statistical Methods
PFS and OS were estimated using the Kaplan–Meier method, and a 
log-rank test was used to compare results between groups of patients 
with vs without HTN. A Pearson x
2 test and Fisher exact test were 
used to compare ORR and selected HTN-associated complications 
between both groups, respectively. The influence on PFS and OS of 
selected  baseline  prognostic  risk  factors  [including  the  Memorial 
Sloan-Kettering Cancer Center (MSKCC) criteria (24) and criteria 
developed for patients with metastatic renal cell carcinoma receiving 
VEGF inhibitors (25)] was analyzed with the use of a Cox propor-
tional hazards model with each factor investigated in univariate and 
then  multivariable  analyses  with  a  backward  stepwise  algorithm. 
Factors in the univariate analysis with a P value of less than .2 were 
entered into the multivariable model, and additional elimination was 
applied to identify statistically significant variables (at the P < .05 level).
A  Cox  proportional  hazards  model  that  considered  onset  of 
HTN  as  a  time-dependent  covariate  was  also  used  to  estimate 
hazard  ratios  for  PFS  and  OS.  Landmark  analyses  using  the 
Kaplan–Meier  method  were  conducted  to  assess  whether  early 
HTN was associated with either PFS or OS. In these analyses, 
HTN  was  defined  by  maximum  SBP  of  at  least  140  mm  Hg   
or DBP of at least 90 mm Hg experienced by the end of cycle 1   
(6 weeks) and cycle 2 (12 weeks). Patients who died or had disease 
progression or death before each landmark were excluded from the 
OS and PFS analyses, respectively.
All P values were two-sided, confidence intervals (CI) were set 
at the 95% level, and no adjustment was made for multiple com-
parisons; thus, P values less than .05 were considered statistically 
significant.  Pearson  correlation  tests  were  used  to  measure  the 
correlation between sunitinib dosing and maximum BP.
Results
Patients
Most patients in the four trials included in this retrospective analysis 
were men with a mean age of 56–62 years. Most had an ECOG PS of 
0 or 1, had undergone prior nephrectomy, and had metastatic renal 
cell carcinoma with clear cell histology. Baseline patient characteristics 
were typical for patients with metastatic renal cell carcinoma (Table 1).
Table 1. Baseline patient characteristics*
Characteristic
Phase II trial 1  
(N = 63)
Phase II trial 2  
(N = 106)
Phase III trial  
(N = 375)†
Expanded access   
trial (N = 4371)‡
Mean age, y (range) 60 (24–87) 56 (32–79) 62 (27–87) 59.0 (19.0–89.0)
Male/female, % 68/32 63/37 71/29 74/26
ECOG PS, n (%)      
  0 34 (54) 58 (55) 231 (62) 1823 (42)
  1 29 (46) 48 (45) 144 (38) 1872 (43)
  2 0 0 0 503 (12)
  3 0 0 0 73 (2)
  4 0 0 0 6 (<1)
Histology, n (%)      
  Clear cell 55 (87) 105 (99) 375 (100) 3758 (86)
  Other 8 (13) 1 (1) 0 588 (13)
Prior nephrectomy, n (%) 58 (92) 106 (100) 340 (91) 3873 (89)
Prior cytokine therapy, n (%) 63 (100) 106 (100) 0 2974 (68)
Prior radiation therapy, n (%) 25 (40) 20 (19) 53 (14) NA
No. of disease sites, n (%)      
  0 0 0 0 49 (1)
  1 8 (13) 13 (12) 55 (15) 833 (19)
  ≥2 55 (87) 93 (88) 320 (85) 3489 (80)
*  Data are from four clinical trials: phase II trial 1 (19), phase II trial 2 (20), phase III trial (21), expanded access trial (18). ECOG PS = Eastern Cooperative Oncology 
Group performance status; NA = not available.
†  The 375 patients cited in the table are those who were randomized to receive sunitinib in this trial.
‡  The sample of 4371 patients in the expanded access trial, as cited in this table, differs from the total number of patients included in the safety analysis (n = 4373) 
due to different data cutoff dates; as a result, the safety analysis population included 4917 patients.766   Articles | JNCI  Vol. 103, Issue 9  |  May 4, 2011
BP Assessment and HTN Status
Among  those  patients  who  had  HTN  while  on  treatment,  as 
defined by post-baseline maximum SBPs of at least 140 mm Hg or 
maximum DBPs of at least 90 mm Hg, median baseline SBP to 
DBP ratio was 132 mm Hg over 80 mm Hg. Among those patients 
who did not have HTN while on treatment by the same criterion, 
median baseline SBP to DBP ratio was 120 mm Hg over 70 mm 
Hg.  Of  the  544  patients  included  in  the  efficacy  analyses,  442 
(81%) had systolic-defined HTN and 363 (67%) had diastolic-
defined HTN, each recorded at any time after cycle 1, day 1. Of 
note, the incidences of HTN as defined in this analysis were more 
frequent than those in which HTN was reported as an adverse 
event (12) because of the different measures of absolute SBP over 
DBP and CTCAE grading used. The onset of treatment-induced 
HTN  was  early,  with  median  times  to  systolic-  and  diastolic-
defined  HTN  during  cycle  1  (range  1–20)  and  cycle  2  (range 
1–19), respectively. We found that 58% of patients had systolic-
defined HTN and 48% had diastolic-defined HTN by the end of 
cycle 1; 80% had systolic-defined HTN and 68% had diastolic-
defined HTN by the end of cycle 2. The median (range) post-
baseline  SBP  to  DBP  ratio  in  patients  with  HTN  was  160 
(140–220) mm Hg over 98 (90–129) mm Hg, whereas the median 
(range) post-baseline SBP to DBP ratio in patients without HTN 
was 130 (100–139) mm Hg over 82 (59–89) mm Hg.
Relative sunitinib dose intensity (the ratio of actual sunitinib 
dose intensity received to intended sunitinib dose intensity) was 
weakly correlated with maximum SBP (r = .13) and DBP (r = .17). 
Cumulative sunitinib dose up to the time of maximum BP was also 
weakly correlated with maximum SBP (r = .33) and DBP (r = .27).
Association of HTN With Antitumor Efficacy of Sunitinib
Median PFS (figure not shown) and OS (Figure 1) were differen-
tiated by HTN status, as defined by a maximum SBP of at least 140 
mm Hg or a maximum DBP of at least 90 mm Hg, and develop-
ment of treatment-induced HTN was associated with better clin-
ical outcomes (Table 2). The ORR was 54.8% in patients with vs 
Figure 1. Kaplan–Meier estimates of overall survival (OS) by hypertension (HTN) status (post-cycle 1, day 1). In (A) HTN is defined by a maximum 
systolic blood pressure of at least 140 mm Hg. In (B), HTN is defined by a maximum diastolic blood pressure of at least 90 mm Hg. N = number 
at risk; S = survival percentage, with 95% confidence interval (CI) in parentheses.jnci.oxfordjournals.org    JNCI | Articles 767
8.7% in patients without a maximum SBP of at least 140 mm Hg 
(P < .001). Median PFS was 12.5 months (95% CI = 10.9 to 13.7 
months) vs 2.5 months (95% CI = 2.3 to 3.8 months), and median 
OS  was  30.9  months  (95%  CI  =  27.9  to  33.7  months)  vs  7.2 
months (95% CI = 5.6 to 10.7 months) in the same two groups, 
respectively. Results were similar when HTN status was defined 
by a maximum DBP of at least 90 mm Hg (Table 2).
When we looked for an association of median OS with HTN 
status and defined HTN as a mean (instead of maximum) SBP of 
at least 140 mm Hg or a mean DBP of at least 90 mm Hg, we 
observed  similar  results,  although  to  a  lesser  extent  (data  not 
shown). However, we observed no difference in median PFS when 
HTN status was defined by mean BP thresholds.
To determine whether or not antihypertensive agents reduced 
the antitumor efficacy of sunitinib given the observed association 
of  HTN  with  efficacy,  clinical  outcomes  were  compared  in 
patients using these medications at baseline with those who were 
not using antihypertensive agents. There was no statistically signif-
icant difference in ORR between patients who were taking antihy-
pertensive agents at baseline (n = 213) and those who were not   
(n = 331; P = .379). Median PFS in patients taking antihypertensive 
agents at baseline (n = 213) compared with those who were not   
(n = 331) was 11.3 months (95% CI = 10.6 to 13.7 months) com-
pared with 10.6 months (95% CI = 8.3 to 11.0 months; P = .020), 
and median OS was 31.8 months (95% CI = 25.5 to 40.1 months) 
vs 21.4 months (95% CI = 18.2 to 25.0 months; P < .001).
To address potential bias from patients who lived longer having 
longer  drug  exposure  and,  therefore,  greater  opportunity  to   
develop HTN, we used a Cox proportional hazards model with the 
onset of HTN as a time-dependent covariate. The relative risk of 
renal cell carcinoma progression and death decreased in patients 
who developed HTN while on sunitinib with statistical signifi-
cance in three of the four indices evaluated (Table 3). That is, PFS 
and OS were both improved (HR = .603, 95% CI = .451 to .805; 
and HR = .332, 95% CI = .252 to .436, respectively; P < .001 for 
both) in patients with treatment-induced HTN defined by max-
imum SBP. Overall survival (HR = .585, 95% CI = .463 to .740; P 
< .001), but not PFS, was improved in patients with treatment-
induced HTN defined by maximum DBP.
To address potential bias from misclassification of patients who 
may not have remained on study long enough for HTN to be 
observed, landmark analyses were conducted that explored the re-
lationship between HTN and clinical outcome. Patients with vs 
without HTN at the end of cycle 1 (figures not shown), as defined 
by  maximum  SBP  of  at  least  140  mm  Hg,  had  a  PFS  of  13.4 
months (95% CI = 11.0 to 14.3 months) vs 10.8 months (95% CI 
= 9.8 to 13.4 months; P = .031) and an OS of 32.2 months (95% CI 
= 28.1 to “not reached” months) vs 20.3 months (95% CI = 17.0 to 
23.2  months;  P  <.  001),  respectively.  Patients  with  vs  without 
HTN at the end of cycle 1, as defined by maximum DBP of at least 
90 mm Hg, had a PFS of 12.0 months (95% CI = 10.7 to 13.6 
months) vs 11.8 months (95% CI = 10.7 to 13.7 months; P = .612) 
and an OS of 30.1 months (95% CI = 23.6 to 32.5 months) vs 23.3 
months (95% CI = 20.3 to 27.9 months; P = .155), respectively.
Patients with vs without HTN at the end of cycle 2, as defined 
by a maximum SBP of at least 140 mm Hg, had a PFS (figure not 
shown) of 13.6 months (95% CI = 12.4 to 16.1 months) vs 10.8 
months  (95%  CI  =  8.8  to  13.4  months;  P  =  .015)  and  an  OS 
(Figure 2) of 31.1 months (95% CI = 27.9 to 35.2 months) vs 18.2 
months (95% CI = 14.0 to 21.0 months; P <. 001). Patients with 
vs without HTN at the end of cycle 2, as defined by maximum 
DBP of at least 90 mm Hg, had a PFS (figure not shown) of 13.6 
Table 2. Objective response and median progression-free and overall survival by hypertension (HTN) status*
Patient HTN status
Total no.  
of patients
Objective response  
rate, n (%)† P‡
Progression-free  
survival (95% CI), mo P‡
Overall survival  
(95% CI), mo P‡
Maximum SBP ≥ 140 mm Hg 442 242 (54.8)   12.5 (10.9 to 13.7)   30.9 (27.9 to 33.7)
Maximum SBP <140 mm Hg 92 8 (8.7) <.001 2.5 (2.3 to 3.8) <.001 7.2 (5.6 to 10.7) <.001
Maximum DBP ≥ 90 mm Hg 363 208 (57.3)   13.4 (11.3 to 13.8)   32.2 (29.3 to 36.1)
Maximum DBP < 90 mm Hg 171 42 (24.6) <.001 5.3 (4.2 to 7.8) <.001 14.9 (12.2 to 18.2) <.001
*  Hypertension was defined as maximum SBP of at least 140 mm Hg or a maximum DBP of at least 90 mm Hg. CI = confidence interval; DBP = diastolic blood 
pressure;  SBP = systolic blood pressure.
†  Complete response plus partial response as assessed by investigators according to Response Evaluation Criteria in Solid Tumors (22).
‡  P values for objective response rate are from a two-sided Pearson x2 test, and P values for progression-free and overall survival are from a two-sided log-rank 
test.
Table 3. Hazard ratios (HRs) for progression-free and overall survival with hypertension (HTN) as a time-dependent covariate in a Cox 
proportional hazards model*
Patient HTN status
Progression-free survival Overall survival
HR (95% CI) P † HR (95% CI) P †
Maximum SBP ≥ 140 mm Hg 0.603 (0.451 to 0.805) <.001 0.332 (0.252 to 0.436) <.001
Maximum DBP ≥ 90 mm Hg 0.992 (0.792 to 1.243) .947 0.585 (0.463 to 0.740) <.001
*  Hypertension was defined as maximum SBP of at least 140 mm Hg or a maximum DBP of at least 90 mm Hg.  CI = confidence interval; DBP = diastolic blood 
pressure;  SBP = systolic blood pressure.
†  P values are from a two-sided log-rank test.768   Articles | JNCI  Vol. 103, Issue 9  |  May 4, 2011
months (95% CI = 11.3 to 16.1 months) vs 13.4 months (95% CI 
= 10.8 to 14.3 months; P = .760) and an OS (Figure 2) of 31.1 
months (95% CI = 25.6 to 34.3 months) vs 23.0 months (95% CI 
= 20.3 to 27.9 months; P = .013), respectively.
To understand how the management of treatment-induced HTN 
might affect subsequent clinical outcomes, we undertook an explor-
atory subset analysis. Patients with HTN were subdivided into four 
hypertensive patient management groups: 1) addition of antihyperten-
sive agent only, 2) sunitinib dose reduction only, 3) both maneuvers, 
and 4) neither maneuver. Graphical analysis of PFS (figure not shown) 
and OS (Figure 3) demonstrated that patients with HTN (as defined 
by a maximum SBP of at least 140 mm Hg) continued to survive 
longer than patients without HTN, independent of use of antihyper-
tensive agents, HTN-induced dose reductions, or both.
Progression-Free and Overall Survival According to 
Pretreatment Prognostic Risk Factors and HTN Status
A multivariable analysis that included MSKCC risk factors (24) and 
other variables (25) indicated that treatment-induced HTN remained 
a  statistically  significant  predictor  of  survival  benefit  (P  <  .001) 
regardless of how HTN was defined (Table 4) and regardless of 
potential  confounding  influences.  Potential  confounders  included 
other prognostic markers for PFS (ECOG PS, time from diagnosis 
to treatment, age, platelet count, and lactate dehydrogenase) and for 
OS (ECOG PS, time from diagnosis to treatment, lactate dehydro-
genase, corrected calcium, platelet count, and antihypertensive drug 
at baseline; all Ps < .05). Other potential prognostic factors evaluated 
included sex, race, hemoglobin levels, prior nephrectomy, and abso-
lute neutrophil count.
Figure 2. Kaplan–Meier estimates of overall 
survival (OS) by hypertension (HTN) status 
experienced by the end of cycle 2 (12 weeks). 
In (A), HTN is defined by a maximum systolic 
blood pressure  of at least 140 mm Hg. In (B), 
HTN is defined by a diastolic blood pressure 
 of at least 90 mm Hg. N = number at risk; S 
=  survival  percent,  with  95%  confidence 
interval (CI) in parentheses.jnci.oxfordjournals.org    JNCI | Articles 769
Association of HTN With HTN-Related Complications
To  understand  the  clinical  significance  of  treatment-induced 
HTN,  the  incidence  of  cardiovascular,  cerebrovascular,  ocular, 
and renal adverse events of any cause at any grade or at grade 3 or 
higher in sunitinib-treated patients were evaluated in patients with 
and without HTN, as defined by a mean SBP of at least 140 mm 
Hg. Mean (and not maximum) BP measurements were chosen for 
the safety analyses because the elevation of BP over time would be 
more likely to affect end-organ function than elevation at just a 
single maximum time point. The overall incidence of cardiovascu-
lar, cerebrovascular, and ocular adverse events was low, and it was 
similar  between  patients  in  both  groups  (Table  5).  However, 
patients with HTN had somewhat more renal adverse events than 
patients without HTN (any-grade severity: 5% vs 3%, P = .013; 
severity  at  grade  3  or  higher:  3%  vs  2%,  P  =  .045).  Similarly, 
patients with HTN had slightly more adverse events of any-grade 
severity  for  all  renal  failure  preferred  terms  combined  than 
patients without HTN (P = .014), although this difference was not 
statistically significant when events of grade 3 or higher severity 
were compared (P = .155).
The median duration of treatment was defined as the date of 
the first dose to either the date of the last dose plus 28 days, or the 
end-of-study date, whichever occurred first (although treatment-
related  adverse  events  could  have  been  reported  beyond  this 
adverse event reporting period). Median duration of treatment was 
42.4 (range 0.1–182) weeks for 1,045 patients with a mean SBP of 
at least 140 mm Hg and 38.4 (range 0.7–197) weeks for 3,374 
patients with a mean SBP below 140 mm Hg.
Discussion
In this retrospective exploratory analysis of HTN as a biomarker of 
efficacy in more than 500 patients with metastatic renal cell carci-
noma treated with sunitinib, which to our knowledge may be the 
largest  such  investigation  to  date,  sunitinib  treatment–induced 
HTN was associated with statistically significantly improved clinical 
outcome. These findings support the hypothesis that HTN may be 
a viable biomarker of antitumor efficacy in this patient population, 
although  development  of  HTN  during  sunitinib  treatment  was 
neither necessary nor sufficient for clinical benefit in all patients. 
Median PFS and OS were more than fourfold longer for patients 
with HTN than for patients without HTN as defined by a max-
imum SBP of at least 140 mm Hg. In addition, ORR was more than 
six times greater in patients with HTN than in patients without 
HTN. Moreover, a Cox proportional hazards model, with the onset 
of HTN as a time-dependent covariate, demonstrated a statistically 
significant decrease in the relative risk of both disease progression 
and death in patients who developed HTN, as defined by maximum 
SBP (and in the relative risk of death but not disease progression, 
with  HTN  defined  by  maximum  DBP).  Importantly,  landmark 
analyses of HTN onset by the end of the first or second treatment 
cycle were also associated with improved clinical outcome. These 
data, combined with a multivariable analysis of baseline prognostic 
factors that showed that HTN (particularly systolic-defined HTN) 
was a statistically significant predictor of clinical outcome, provide 
further support to the growing body of evidence that VEGF path-
way inhibitors are associated with treatment-induced HTN, which, 
in turn, may be a correlative biomarker of antitumor efficacy.
Figure 3. Kaplan–Meier estimates of overall 
survival (OS) by hypertension (HTN) control 
and status. HTN was defined by a maximum 
systolic blood pressure  of at least 140 mm 
Hg (post-cycle 1, day 1). N = number at risk; 
NR = not reached; S = survival percent, with 
95% confidence interval (CI) in parentheses.770   Articles | JNCI  Vol. 103, Issue 9  |  May 4, 2011
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.
The  incidence  of  HTN-associated  adverse  events  in  nearly 
5000  sunitinib-treated  patients  with  metastatic  renal  cell  carci-
noma was low and was generally similar between patients in this 
study who did and did not develop HTN (defined as mean SBP of 
at least 140 mm Hg), supporting the acceptability of HTN as a 
biomarker of efficacy. This is testimony to the general tolerability 
and manageability of this adverse event through standard antihy-
pertensive therapy and/or dose schedule modification; however, 
patients with HTN had a slightly higher incidence of renal adverse 
events  than  patients  without  HTN.  This  mirrors  a  recently 
reported systematic review of the published literature by Zhu et al. 
(26) that found a notably increased risk for high-grade HTN (rel-
ative risk [RR] = 22.72; P < .001) but only a small increased risk for 
renal dysfunction (RR = 1.36; P < .001) in patients treated with 
sunitinib compared with control subjects (the majority of whom 
had  renal  cell  carcinoma  or  gastrointestinal  stromal  tumor).  In 
addition, a recent study by Launay-Vacher et al. (27) found that 
renal function (as assessed by glomerular filtration rate) in patients 
with  renal  cell  carcinoma  who  received  antiangiogenic  therapy 
after  unilateral  nephrectomy  declined  over  time  (more  so  in 
patients who had HTN before initiation of therapy). However, it 
is unclear whether the apparent differences in adverse events in our 
study (recorded as kidney system organ class any-grade and grade 
3 or higher; and combined renal failure, any-grade but not grade 3 
or higher) are clinically important. This potential risk warrants 
additional prospective investigation.
These data and the potential for renovascular complications 
underscore the importance of monitoring patients with metastatic 
renal cell carcinoma for sunitinib-induced HTN and treating them 
as necessary with antihypertensive medication, as recently recom-
mended by an expert panel of the National Cancer Institute for 
patients receiving VEGF inhibitors (28). Management of HTN 
may or may not include dose reduction, taking into account the 
findings reported herein that use of antihypertensive agents did 
not reduce sunitinib antitumor activity. Similarly, a prospective 
study of HTN management in patients with solid tumors who 
received  the  potent  and  selective  VEGF  inhibitor,  cediranib, 
found  that  “antihypertensive  prophylaxis”  did  not  reduce  the 
tumor response despite reducing the incidence of severe HTN 
(29). In addition, studies have shown that aggressive BP moni-
toring and treatment for HTN via use of a prespecified algorithm, 
rather than commonly used toxicity criteria, may achieve uninter-
rupted full-dose therapy with sunitinib (30) thus further improving 
the opportunity for improved clinical outcome. Use of HTN as a 
biomarker of efficacy may complement such a management ap-
proach, providing evidence of antitumor efficacy without appre-
ciable increased risk of HTN-associated complications, thereby 
optimizing the therapeutic benefit of sunitinib.
The mechanism by which sunitinib and other antiangiogenic 
agents  induce  HTN  requires  further  elucidation,  but  several 
studies have begun to shed light on this question. For example, 
antagonism  of  VEGF  has  been  shown  to  decrease  nitric  oxide 
production, leading to a constriction of the vasculature and a re-
duction in sodium ion renal excretion, resulting in HTN (31,32). 
Furthermore, a recent study found that sunitinib treatment was 
associated with a statistically significant reduction of capillary den-
sity (P < .01) that was significantly correlated with changes in vessel jnci.oxfordjournals.org    JNCI | Articles 771
morphology  (and  increased  SBP  [r  =  2.57;  P  <  .05]  and  DBP 
[r = 2.68; P < .01]), both of which were statistically significantly 
associated with prolonged PFS (P = .044) (33). Additional evidence 
indicates involvement of other renovascular mechanisms (10).
It may be hypothesized that the susceptibility of normal blood 
vessels to VEGF blockade, leading to HTN, is linked to the sus-
ceptibility of tumor vessels to VEGF blockade, resulting in a more 
robust  antiangiogenic  effect  in  response  to  sunitinib  treatment, 
and thus, an enhanced clinical outcome. The precise mechanism(s) 
whereby VEGF inhibition leads to HTN and, further, the best 
means to exploit those mechanisms for clinical benefit in meta-
static renal cell carcinoma and other tumor types requires addi-
tional investigation. Antihypertensive medication use at baseline 
remained statistically significantly associated with OS in the mul-
tivariable  model,  independent  of  other  factors,  including  treat-
ment-induced  HTN.  Also,  the  addition  of  antihypertensive 
medication did not adversely affect the favorable clinical outcome 
for hypertensive patients. These data further support the hypo-
thesis that this phenomenon is a host effect. That is, inherent host 
biology (which predisposes one to both baseline and treatment-
induced HTN) is intertwined with the biology of the antitumor 
effect of VEGF blockade, though the possibility that HTN itself 
predicts a more favorable outcome independent of the effect of 
VEGF inhibition cannot completely be excluded. The multiple 
hypotheses generated here warrant testing in prospective clinical 
trials to validate these findings and standardize the criteria for the 
use of HTN as a biomarker of VEGF pathway inhibitor efficacy.
There are several limitations of the current investigation. Such 
limitations include variability in BP characteristics among studies, 
lack  of  full  pharmacokinetic  data,  and  lack  of  consensus  about 
which  BP  parameter  is  most  reliably  measured  in  this  setting. 
Relative  sunitinib  dose  intensity  and  cumulative  sunitinib  dose 
only weakly correlated with maximum BP in our analysis. In addi-
tion,  a  recently  published  pharmacokinetic–pharmacodynamic 
meta-analysis by Houk et al. (34) demonstrated a weak correlation 
(r = 0.29) between changes in DBP and trough plasma concen-
trations,  indicating  substantial  interpatient  variability  in  DBP   
elevation  at  given  sunitinib  trough  plasma  concentrations,  in 
Table 5. Hypertension (HTN)-associated adverse events of any cause related to the brain, eye, heart, and kidney by HTN status*
No. of patients (%)
Without HTN (n = 3374) With HTN (n = 1045) Total (N = 4917)†
Adverse event Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Any HTN-associated adverse event‡ 300 (9) 116 (3) 112 (11) 46 (4) 439 (9) 177 (4)
Brain 13 (<1) 8 (<1) 7 (1) 3 (<1) 20 (<1) 11 (<1)
  Cerebral hematoma 2 (<1) 1 (<1) 1 (<1) 0 3 (<1) 1 (<1)
  RPLS 1 (<1) 1 (<1) 1 (<1) 0 2 (<1) 1 (<1)
  Transient ischemic attack 10 (<1) 6 (<1) 5 (<1) 3 (<1) 15 (<1) 9 (<1)
Eye 123 (4) 3 (<1) 40 (4) 1 (<1) 170 (3) 4 (<1)
  Vision blurred 69 (2) 2 (<1) 14 (1) 0 84 (2) 2 (<1)
  Vision acuity reduced 10 (<1) 1 (<1) 4 (<1) 1 (<1) 17 (<1) 2 (<1)
  Visual disturbance 47 (1) 0 23 (2) 0 73 (1) 0
  Visual field defect 3 (<1) 0 0 0 3 (<1) 0
  Visual field defect NOS 1 (<1) 0 0 0 1 (<1) 0
Heart 63 (2) 50 (1) 16 (2) 14 (1) 86 (2) 68 (1)
  Cardiac failure 18 (1) 15 (<1) 9 (1) 8 (1) 30 (1) 24 (<1)
  Cardiac failure congestive 12 (<1) 10 (<1) 3 (<1) 3 (<1) 15 (<1) 13 (<1)
  Left ventricular dysfunction 17 (1) 11 (<1) 1 (<1) 0 20 (<1) 12 (<1)
  Myocardial infarction 19 (1) 16 (<1) 3 (<1) 3 (<1) 24 (<1) 21 (<1)
Kidney§ 116 (3) 61 (2) 54 (5) 30 (3) 184 (4) 103 (2)
  Nephrotic syndrome 2 (<1) 1 (<1) 2 (<1) 2 (<1) 4 (<1) 3 (<1)
  Proteinuria 43 (1) 12 (<1) 17 (2) 6 (<1) 60 (1) 18 (<1)
  Proteinuria present 0 0 1 (<1) 1 (<1) 1 (<1) 1 (<1)
  Renal failure¶ 44 (1) 26 (1) 27 (3) 12 (1) 81 (2) 47 (1)
  Renal failure NOS¶ 1 (<1) 1 (<1) 0 0 1 (<1) 1 (<1)
  Renal failure acute¶ 30 (1) 21 (1) 11 (1) 10 (1) 46 (1) 34 (1)
  Thrombotic microangiopathy 1 (<1) 1 (<1) 0 0 1 (<1) 1 (<1)
  Thrombotic thrombocytopenic purpura 2 (<1) 2 (<1) 1 (<1) 1 (<1) 3 (<1) 3 (<1)
*  HTN was defined as mean systolic blood pressure of at least 140 mm Hg.  NCI CTCAE = National Cancer Institute Common Terminology Criteria for Adverse 
Events; NOS = not otherwise specified; RPLS = reversible posterior leukoencephalopathy syndrome.
†  HTN status was missing for 498 patients, of whom 27 (5%) and 15 (3%) had any-grade and grade 3 or higher HTN-associated adverse events, respectively.
‡  The absence of a preferred term under each HTN-associated complication system organ class indicates the absence of a reported adverse event (Note: the 
general NCI CTCAE, version 3.0 guidelines for grading adverse event severity may have been followed for adverse event grades that the NCI CTCAE does not 
recognize as appropriate for that adverse event term).
§  Using Fisher exact test, a comparison between patients with vs without HTN was statistically significant (P = .0129) for kidney system organ class adverse 
events of any-grade severity and was also statistically significant for adverse events of grade 3 or higher severity (P = .0451).
¶  Using a two-sided Fisher exact test, a comparison between patients with vs without HTN was statistically significant (P = .0136) for all renal failure preferred 
terms combined of any-grade severity but was not statistically significant for renal failure of grade 3 or higher severity (P = .1548).772   Articles | JNCI  Vol. 103, Issue 9  |  May 4, 2011
predominantly patients with renal cell carcinoma and gastrointes-
tinal  stromal  tumor  (including  patients  from  the  two  phase  II 
metastatic  renal  cell  carcinoma  studies  used  in  our  analysis). 
However, further studies are warranted to confirm that sunitinib-
induced HTN is a “true” biomarker of efficacy and not simply an 
epiphenomenon of higher drug exposure, a possibility that cannot 
be definitively excluded given the inherent limitations of a retro-
spective analysis.
The investigation into predictive biomarkers for response to 
antiangiogenic therapy is a high priority. Although these agents 
have broad antitumor activity, most notably as single agents in 
the treatment of metastatic renal cell carcinoma, there is, at pre-
sent, no prospectively validated biomarker upon which to choose 
a specific therapy. The ideal biomarker would be simple, reflec-
tive of intended target inhibition, easy to measure, of low cost, 
and  reliably  present  at  baseline  or  early  after  initiation  of 
therapy.  Although  several  potential  biomarkers  have  been  re-
cently investigated in renal cell carcinoma, including functional 
imaging,  other  treatment-related  adverse  events,  circulating 
VEGF pathway proteins or endothelial cells, and VEGF single-
nucleotide  polymorphisms  (35),  none  have  been  consistently   
associated  with  patient  outcomes  as  demonstrated  here. 
Furthermore, each of these modalities requires a substantial in-
vestment  of  patient  resources,  time,  cost,  and  expertise. 
Therefore, because it is more manageable than other potential 
adverse event biomarkers, treatment-induced HTN, if prospec-
tively  validated,  may  best  meet  the  criteria  for  a  desirable   
biomarker in patients with advanced renal cell carcinoma treated 
with sunitinib.
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